Bulevirtide for Hep D: Phase 3 Data Now Published in NEJM Bulevirtide for Hep D: Phase 3 Data Now Published in NEJM

Bulevirtide, an investigational, first-in-class hepatitis delta virus entry-inhibitor, significantly reduced viral load and normalized liver enzymes in patients.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news